Daily app-based symptom recording is more efficient than SAQ or ETT for detecting antianginal treatment effects, enabling patient-centered estimands that improve clinical interpretability. Derived estimands from ORBITA-2 showed PCI reduced 31.4 angina episodes and added 14.5 angina-free days vs placebo over 12 weeks (Pr[benefit] >0.99).